NBT Bank N A NY lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 15.5% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 34,892 shares of the biopharmaceutical company’s stock after selling 6,380 shares during the quarter. NBT Bank N A NY’s holdings in Gilead Sciences were worth $2,470,000 at the end of the most recent quarter.
Other large investors have also bought and sold shares of the company. Nwam LLC boosted its position in shares of Gilead Sciences by 9.6% in the first quarter. Nwam LLC now owns 12,404 shares of the biopharmaceutical company’s stock worth $842,000 after acquiring an additional 1,084 shares during the last quarter. Searle & CO. lifted its position in Gilead Sciences by 0.6% during the first quarter. Searle & CO. now owns 13,350 shares of the biopharmaceutical company’s stock valued at $907,000 after buying an additional 80 shares in the last quarter. Pillar Pacific Capital Management LLC lifted its position in Gilead Sciences by 1.0% during the first quarter. Pillar Pacific Capital Management LLC now owns 105,354 shares of the biopharmaceutical company’s stock valued at $7,155,000 after buying an additional 1,055 shares in the last quarter. Trust Investment Advisors lifted its position in Gilead Sciences by 10.3% during the first quarter. Trust Investment Advisors now owns 6,420 shares of the biopharmaceutical company’s stock valued at $436,000 after buying an additional 600 shares in the last quarter. Finally, Capital One National Association lifted its position in Gilead Sciences by 2.5% during the first quarter. Capital One National Association now owns 20,219 shares of the biopharmaceutical company’s stock valued at $1,373,000 after buying an additional 484 shares in the last quarter. Hedge funds and other institutional investors own 74.62% of the company’s stock.
Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at $72.85 on Tuesday. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $86.27. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68. The stock has a market capitalization of $93,930.00, a price-to-earnings ratio of 7.70, a P/E/G ratio of -1.24 and a beta of 1.13.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The business had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. During the same quarter last year, the business posted $2.75 earnings per share. The company’s revenue for the quarter was down 13.2% on a year-over-year basis. equities analysts expect that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be issued a $0.52 dividend. The ex-dividend date is Thursday, December 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.86%. Gilead Sciences’s dividend payout ratio is currently 23.66%.
In other news, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $83.11, for a total value of $6,094,705.63. Following the transaction, the insider now owns 2,996,766 shares in the company, valued at $249,061,222.26. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Gregg H. Alton sold 50,000 shares of the business’s stock in a transaction dated Wednesday, August 30th. The shares were sold at an average price of $79.00, for a total value of $3,950,000.00. Following the transaction, the executive vice president now owns 113,237 shares in the company, valued at approximately $8,945,723. The disclosure for this sale can be found here. In the last quarter, insiders sold 446,819 shares of company stock worth $36,269,486. Company insiders own 1.30% of the company’s stock.
GILD has been the subject of a number of research analyst reports. Argus lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating and lifted their price target for the stock from $73.25 to $73.77 in a research note on Monday. Mizuho boosted their target price on shares of Gilead Sciences from $77.00 to $83.00 and gave the company a “buy” rating in a research note on Wednesday, November 8th. Maxim Group reissued a “hold” rating on shares of Gilead Sciences in a report on Friday, October 27th. BMO Capital Markets dropped their price target on shares of Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating on the stock in a research report on Friday, October 27th. Finally, J P Morgan Chase & Co set a $85.00 target price on Gilead Sciences and gave the company a “buy” rating in a report on Wednesday, October 25th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $84.87.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.